Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13974108 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2UCHL1DRD4 | |
| SCHEMBL13974252 | 1.00 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2UCHL1DRD4 | |
| SCHEMBL1868500 | 0.93 | UCHL1 (0.41) | UCHL1KMT2A | |
| SCHEMBL1873295 | 0.93 | UCHL1 (0.41) | UCHL1KMT2A | |
| SCHEMBL29771950 | 0.93 | UCHL1 (0.41) | UCHL1KMT2A | |
| SCHEMBL1868501 | 0.93 | UCHL1 (0.41) | UCHL1KMT2A | |
| SCHEMBL17022083 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2DRD4LMNA | |
| SCHEMBL22501388 | 0.86 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2DRD4CA1 | |
| SCHEMBL28677537 | 0.86 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2DRD4CA1 | |
| SCHEMBL24619645 | 0.85 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | BIRC5, BIRC2, BIRC3 | TAS1R3 4578/4885TAS1R1 4403/4885TAS1R2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.